Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 61 of 116

  1. NERATINIB, Sindiar 2 mg cápsulas duras

    Ningbo Cancer Hospital

    HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.

    phase 2 small molecule active

    1 trial

  2. NIVOLUMAB, TEDOPI

    Fondazione Telethon ETS

    metastatic non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  3. NJMU-BC01

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  4. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  5. NK cells

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  6. NK cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  7. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  8. NKTR-102

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  9. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  10. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

  11. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  12. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  13. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  14. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  15. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  16. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  17. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  18. NOV-002

    Cellectar Biosciences

    Leukemia

    phase 2 small molecule terminated

    1 trial

  19. NOV-002

    Cellectar Biosciences

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  20. NP30179

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  21. NP39488

    Hoffmann-La Roche

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  22. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  23. NRX 194204

    IO Biotech

    Castration Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  24. NT219

    PURPLE BIOTECH LTD.

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  25. NT219

    PURPLE BIOTECH LTD.

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  26. NX-5948

    Nurix Therapeutics

    Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    phase 2 small molecule active

    1 trial

  27. NX-5948

    Nurix Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    2 trials

  28. NY-ESO-1 Peptide vaccine

    Coherus Oncology

    Ovarian Cancer Stage IV

    phase 2 mab active

    1 trial

  29. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  30. Nab paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  31. Nab-PIPAC

    Fondazione Telethon ETS

    Pancreatic cancer with peritoneal metastases

    phase 2 small molecule active

    1 trial

  32. Nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  33. Nab-paclitaxel Combined With Cadonilimab (AK104)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  34. Nadunolimab

    Coherus Oncology

    Metastatic Microsatellite Stable Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  35. Namodenoson 25mg

    Can-Fite BioPharma

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  36. Nenocorilant 200 mg

    CORCEPT THERAPEUTICS INC

    Neoplasms

    phase 2 small molecule active

    1 trial

  37. NeoART

    The George Institute

    HER2 positive resectable esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  38. NeoMatryx

    The George Institute

    Merkel Cell Carcinoma

    phase 2 small molecule active

    1 trial

  39. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  40. Neoadjuvant Chemotherapy (NACT)

    The First People's Hospital of Lianyungang

    HR+/HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  41. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  42. Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  43. Neoadjuvant Therapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  44. Neoadjuvant therapy: TCbHPy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  45. Neoantigen specific TCR-T cell drug product

    Alaunos Therapeutics

    Gynecologic Cancer

    phase 2 mab terminated

    1 trial

  46. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  47. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  48. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.